SLC7A11 and hepatocellular carcinoma: The expression of SLC7A11 in GBM [152,153], CD133-positive hepatocellular carcinoma cells [154], poorly differentiated liver cancer tissues [92], and metastatic and/or recurrent urothelial carcinoma [93] was downregulated via multiple mechanisms of interference to inhibit GSH synthesis, induce intracellular ROS levels, and increase sensitivity to chemotherapy drugs.